Cover Image
市場調查報告書

精神分裂症(思覺失調症) : 開發中產品分析

Schizophrenia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232781
出版日期 內容資訊 英文 349 Pages
訂單完成後即時交付
價格
Back to Top
精神分裂症(思覺失調症) : 開發中產品分析 Schizophrenia - Pipeline Review, H2 2016
出版日期: 2016年11月09日 內容資訊: 英文 349 Pages
簡介

精神分裂症是會造成慢性嚴重腦功能障礙的疾病,一般症狀會在青年後期及成年早期出現。症狀有妄想、幻覺、支離破碎的會話及行動。危險因子有家族病史,年齡,藥物(精神活性藥),免疫系統低等。治療採用抗精神病藥。

本報告提供思覺失調症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新新聞及發表的企業和研究機關開發中的治療藥、治療藥評估、後期階段及中止的計劃等相關資訊。

簡介

  • 思覺失調症 概要

治療藥的開發

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

治療藥的評估

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8727IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Pipeline Review, H2 2016, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Schizophrenia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 10, 13, 30, 1, 53, 10 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 8 and 2 molecules, respectively.Schizophrenia.

Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Schizophrenia Overview
  • Therapeutics Development
  • Schizophrenia - Therapeutics under Development by Companies
  • Schizophrenia - Therapeutics under Investigation by Universities/Institutes
  • Schizophrenia - Pipeline Products Glance
  • Schizophrenia - Products under Development by Companies
  • Schizophrenia - Products under Investigation by Universities/Institutes
  • Schizophrenia - Companies Involved in Therapeutics Development
  • Schizophrenia - Therapeutics Assessment
  • Drug Profiles
  • Schizophrenia - Dormant Projects
  • Schizophrenia - Discontinued Products
  • Schizophrenia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Schizophrenia, H2 2016
  • Number of Products under Development for Schizophrenia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Schizophrenia - Pipeline by Adamed Sp. z o.o., H2 2016
  • Schizophrenia - Pipeline by Aequus Pharmaceuticals Inc., H2 2016
  • Schizophrenia - Pipeline by Aestus Therapeutics, Inc., H2 2016
  • Schizophrenia - Pipeline by AgeneBio Inc., H2 2016
  • Schizophrenia - Pipeline by Alkermes Plc, H2 2016
  • Schizophrenia - Pipeline by Angita B.V., H2 2016
  • Schizophrenia - Pipeline by Astellas Pharma Inc., H2 2016
  • Schizophrenia - Pipeline by Athersys, Inc., H2 2016
  • Schizophrenia - Pipeline by Avanir Pharmaceuticals, Inc., H2 2016
  • Schizophrenia - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2016
  • Schizophrenia - Pipeline by BCWorld Pharm Co. Ltd., H2 2016
  • Schizophrenia - Pipeline by BioCrea GmbH, H2 2016
  • Schizophrenia - Pipeline by BioHealthonomics Inc, H2 2016
  • Schizophrenia - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Schizophrenia - Pipeline by Braeburn Pharmaceuticals, Inc., H2 2016
  • Schizophrenia - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Schizophrenia - Pipeline by Critical Pharmaceuticals Limited, H2 2016
  • Schizophrenia - Pipeline by Curemark, LLC, H2 2016
  • Schizophrenia - Pipeline by Delpor, Inc., H2 2016
  • Schizophrenia - Pipeline by Denovo Biopharma, LLC, H2 2016
  • Schizophrenia - Pipeline by Echo Pharmaceuticals B.V., H2 2016
  • Schizophrenia - Pipeline by Egis Gyogyszergyar Nyrt, H2 2016
  • Schizophrenia - Pipeline by Evotec AG, H2 2016
  • Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Schizophrenia - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016
  • Schizophrenia - Pipeline by Galenea Corp., H2 2016
  • Schizophrenia - Pipeline by GeNeuro SA, H2 2016
  • Schizophrenia - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2016
  • Schizophrenia - Pipeline by GP Pharm, S.A., H2 2016
  • Schizophrenia - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Schizophrenia - Pipeline by H. Lundbeck A/S, H2 2016
  • Schizophrenia - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Schizophrenia - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016
  • Schizophrenia - Pipeline by Indivior Plc, H2 2016
  • Schizophrenia - Pipeline by INSYS Therapeutics, Inc., H2 2016
  • Schizophrenia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016
  • Schizophrenia - Pipeline by IntelGenx Corp., H2 2016
  • Schizophrenia - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
  • Schizophrenia - Pipeline by Jiangsu Nhwa Pharmaceutical Corporation Ltd., H2 2016
  • Schizophrenia - Pipeline by Johnson & Johnson, H2 2016
  • Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc., H2 2016
  • Schizophrenia - Pipeline by KemPharm, Inc., H2 2016
  • Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2016
  • Schizophrenia - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Schizophrenia - Pipeline by Lohocla Research Corporation, H2 2016
  • Schizophrenia - Pipeline by Luye Pharma Group Ltd., H2 2016
  • Schizophrenia - Pipeline by Mapi Pharma Ltd., H2 2016
  • Schizophrenia - Pipeline by Merck & Co., Inc., H2 2016
  • Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Schizophrenia - Pipeline by Neurocrine Biosciences, Inc., H2 2016
  • Schizophrenia - Pipeline by NeurOp, Inc, H2 2016
  • Schizophrenia - Pipeline by Newron Pharmaceuticals S.p.A., H2 2016
  • Schizophrenia - Pipeline by Omeros Corporation, H2 2016
  • Schizophrenia - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Schizophrenia - Pipeline by Peptron, Inc., H2 2016
  • Schizophrenia - Pipeline by Pfizer Inc., H2 2016
  • Schizophrenia - Pipeline by Promentis Pharmaceuticals, Inc., H2 2016
  • Schizophrenia - Pipeline by Ra Pharmaceuticals, Inc., H2 2016
  • Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
  • Schizophrenia - Pipeline by Richter Gedeon Nyrt., H2 2016
  • Schizophrenia - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Schizophrenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016
  • Schizophrenia - Pipeline by Suven Life Sciences Ltd., H2 2016
  • Schizophrenia - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016
  • Schizophrenia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Schizophrenia - Pipeline by Tetra Discovery Partners LLC, H2 2016
  • Schizophrenia - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc., H2 2016
  • Schizophrenia - Pipeline by Vitality Biopharma Inc, H2 2016
  • Schizophrenia - Pipeline by VLP Therapeutics, LLC, H2 2016
  • Schizophrenia - Pipeline by Zogenix, Inc., H2 2016
  • Schizophrenia - Pipeline by Zysis Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Schizophrenia - Dormant Projects, H2 2016
  • Schizophrenia - Dormant Projects (Contd..1), H2 2016
  • Schizophrenia - Dormant Projects (Contd..2), H2 2016
  • Schizophrenia - Dormant Projects (Contd..3), H2 2016
  • Schizophrenia - Dormant Projects (Contd..4), H2 2016
  • Schizophrenia - Dormant Projects (Contd..5), H2 2016
  • Schizophrenia - Dormant Projects (Contd..6), H2 2016
  • Schizophrenia - Dormant Projects (Contd..7), H2 2016
  • Schizophrenia - Dormant Projects (Contd..8), H2 2016
  • Schizophrenia - Dormant Projects (Contd..9), H2 2016
  • Schizophrenia - Dormant Projects (Contd..10), H2 2016
  • Schizophrenia - Dormant Projects (Contd..11), H2 2016
  • Schizophrenia - Dormant Projects (Contd..12), H2 2016
  • Schizophrenia - Dormant Projects (Contd..13), H2 2016
  • Schizophrenia - Discontinued Products, H2 2016
  • Schizophrenia - Discontinued Products (Contd..1), H2 2016
  • Schizophrenia - Discontinued Products (Contd..2), H2 2016
  • Schizophrenia - Discontinued Products (Contd..3), H2 2016

List of Figures

  • Number of Products under Development for Schizophrenia, H2 2016
  • Number of Products under Development for Schizophrenia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top